Tuesday, August 31, 2021

The Printer -- Nothing About The Bakken -- August 31, 2021

Some months ago, maybe a year ago, perhaps pre-pandemic, I ranted about how much I "hated" Hewlitt Packard -- HP -- when it came to printers. If I find the rant, I will link it. 

The story is too long to repeat here, but the bottom line is this: I needed a new printer. 

I put that purchase off for weeks, if not a month or two, until my wife "demanded" I get her a new printer. There were few choices / few options.

I ended up buying an HP Envy printer for $120 at our local Target store. 

Even after purchasing it, I delayed setting it up; I read too many horror stories regarding initial set-up.

Be that as it may, I finally had to set it up before I went to Montana. 

I was very, very careful to follow set-up instructions exactly as written, and I paused at least two minutes in between each step to ensure the wireless set-up was happening. 

I left printed instructions to my wife how to use the new printer. 

While I was gone, she was able to use the printer and was very, very happy with it.

Since then, I have used it numerous times. 

I love it!

I love the printer.

Wireless. 

I'll leave it at that for now. But I love this printer so much, I plan to buy the same printer for our middle granddaughter, and will likely buy a new Apple iPad for her at the same time.

It is absolutely incredible. The Apple iPad automatically "connects" with the HP Envy printer, no need for any new software to be uploaded. Like so many Apple products, "it simply works."

Target is unable to keep the HP Envy printers in stock. I checked yesterday, in the printer section of Target, the shelves were bare. The shelves could hold about 36 printers on display; in fact, there were only six: three high-end color Canon printers; two Epson (nice) printers; and, one HP printer, a model I did not want.

The Target manager says a Target truck comes in every day, but they never know what will be on the truck. They haven't had a new shipment of HP Envy printers in over two weeks and don't know when the next printers will come in. 

So, we'll check every day.

We got our Envy printer for $120 (we might have had a coupon); Target is currently selling the same model for $130 ($129.99). At Amazon: $139.99.

Ramblings On Investing In General -- August 31, 2021

Market: the market had a huge day yesterday. Today is the last day (and last trading day) of the third quarter. One would expect a huge sell-off as fund managers lock in their third-quarter profits. But so far that hasn't happened. 

My favorite chart, US money market fund monitor, link here. These folks are earning zero percent on their money. They are also ignoring the recent $1 trillion infrastructure bill already passed and the $3.5 trillion social infrastructure bill working its way through the US Congress.

Hold that thought.

Today, from The WSJ: Fidelity wants to add 9,000 jobs by year-end. Move to meet investing demand will boost company's workforce to more than 60,000. 

Of course, this is in addition to all the independent financial advisors who use Fidelity as "their platform" to invest clients' funds.

From the linked article:

Fidelity’s hiring spree is its third in the past year, when millions of new investors flocked to brokerages like Fidelity, Charles Schwab Corp. and Robinhood Markets Inc. Including the latest push, Fidelity’s total workforce is expected to grow more than 22% this year, to over 60,000 employees.

Drawn to the market’s rally, individual investors have changed the fortunes of the brokerage industry. 
The no-commission stock trades and low-fee investment funds now offered by many firms have brought in plenty of new clients. They also have thinned money managers’ profit margins and forced them to compete on price. Traditional products, like stock- and bond-picking mutual funds, have been leaking client money.

There's some disagreement which of the three was the first to introduce commission-free trades: Fidelity, Schwab, or a third firm (whose name I've forgotten). 

*************************
Not Ready For Prime Time

Now back to that investing article I linked some days ago: "84% of retirees are making this RMD mistake."

Link here. 

Pet peeve.

I very much enjoy informative articles on investing but when a writer categorically suggests "84% of retirees are making a mistake with regard to their RMDs" it rankles me. 

In this case, the premise of the "financial advisor" is this: if one takes only the minimum of the RMDs from one's retiree accounts, most retirees (84%?) will leave a lot of money in their retirement accounts at time of death.

Well, la de da.

Maybe, that's their goal, or maybe there are other reasons.

The advice of this writer might hold some water now with the US market doing so well, but if the market collapses and/or if fund managers manage their funds poorly, that advice may be wrong.

Retirees' biggest fear is their "retirement money running out" before they die, and that's why they may be taking the minimum required. I would assume intelligent folks would take out as much money as they need/want, while at the same time taking into consideration how long they might live and whether the market might collapse.

However, the bigger issue is this: the writer implies, or states outright, that folks are only taking the minimum required. What study is that based on? This would be incredibly difficult data to come by. 

 But I digress.

Many folks with retirement accounts and RMDs don't need the money in the first place. For many, it was wonderful when no RMDs were required in 2020 due to Covid-19 (which made no sense, by the way) and it was even more wonderful when the age was moved from 70 1/2 to 72 years of age when RMDs are first required. That was huge and although it looks like it is not going to happen, there were many in Congress who were hoping to advance that age ever further, to age 74 years of age, or even 75 years of age.

If one doesn't need the money, the worst thing to do is take money out of a tax-deferred account. That was the first thing I thought of when reading this article -- and suggests to me that the writer is incredibly naive. If one needs cash, and all things being equal, wouldn't it be better to take money out of a non-tax-deferred account. In fact, if dividends are being automatically reinvested in a non-tax-deferred account, perhaps it would be best to take out those dividends first if one needs cash. They are taxable, regardless.

Suppose I have two accounts side-by-side, one is a tax-deferred-retirement account, the other is a simple brokerage account, taxable, with dividends automatically reinvested.

Suppose I don't need the cash. Perhaps my pension, social security, my spouse's social security, other sources of income, are more than adequate.

Wouldn't it be great if I could substitute / replace the RMDs as required by current law from the tax-deferred account with an identical withdrawal from the non-tax-deferred account. 

If the taxes paid to the IRS were identical, why would the IRS care whether the fungible cash came from one account or the other?

As it is, because of the RMD rules, I won't touch the simple brokerage account -- I will let it grow (hopefully) and leave it to my heirs who will benefit from the stepped-up value rule (unless that changes).

Obviously the writer of this article is much smarter than I so I must be missing something. But for the life of me I would wonder why I would be advised to take more money than necessary from a tax-deferred account. 

My hunch: Congress knew this also, and that's why they established RMDs.

Safer, Less Expensive, Than Aspirin? -- And Actually Therapeutic Against Covid-19? August 31, 2021

I've mentioned this drug on the blog some time ago but I've avoided the subject because I never understood how an anti-parasitic could "fight" a virus.

We're talking about Ivermectin.

So, after a year of avoiding talking about it, I finally looked up its "proposed" mechanism of action that allows it to fight the Covid-19 virus. 

Link here. This comes from our own NIH.gov. Published 2020.

Intro:

Ivermectin ... is a macrocyclic lactone with a broad-spectrum antiparasitic pharmacological activity.

It is the safest and most effective semi-synthetic derivative of the entire class of avermectins, discovered in 1975 by Professor Satoshi Ōmura as fermentation products of the actinomycete bacterium Streptomyces avermitilis ... 

Its main pharmacodynamics is to bind some channel proteins for chlorine controlled by glutamate, typical of specific classes of invertebrates, causing a greater permeability to this electrolyte: all this causes a hyperpolarization of the cell membrane, blocking inhibitory neurotransmission in neurons and myocytes, resulting in paralysis and death. 

Commercialized since 1981, its low cost, its high efficacy and safety, and the marked tropism for helminths (therefore with an almost zero impact on the biochemistry of human beings) have led to its inclusion in the twenty-first World Health Organization's List of Essential Medicines (World Health Organization 2019).

Then this:

Regarding its role as an antiviral agent, its efficacy has been demonstrated on several viruses, both in vitro and in vivo. 

Among the many mechanisms by which it performs its function, the most consolidated one sees ivermectin as an inhibitor of nuclear transport mediated by the importin α/β1 heterodimer, responsible for the translocation of various viral species proteins (HIV-1, SV40), indispensable for their replication. 

This inhibition appears to affect a considerable number of RNA viruses, such as Dengue Virus 1-4, West Nile Virus, Venezuelan Equine Encephalitis Virus, and Influenza. 

In addition, ivermectin has been shown to be effective against the Pseudorabies virus (PRV, with a DNA-based genome), both in vitro and in vivo, using the same mechanism. 

Caly [has] recently shown that the drug also inhibits the replication of the SARS-CoV-2 virus in vitro, however not clarifying how it occurs. 

Since the causative agent of COVID-19 is an RNA virus, it can be reasonably expected an interference with the same proteins and the same molecular processes described above. 

And, then:

However, ivermectin could prove to be a powerful antiviral, therefore also useful for a possible treatment of the new coronavirus associated syndrome, even from a new perspective. 

This could happen assuming its role as an ionophore agent, only hinted in the recent past but never fully described. 

Ionophores are molecules that typically have a hydrophilic pocket which constitutes a specific binding site for one or more ions (usually cations), while its external surface is hydrophobic, allowing the complex thus formed to cross the cell membranes, affecting the hydro-electrolyte balance. 

These chemical species have historically been used to study the mitochondrial respiratory chain and ATP synthesis in eukaryotes (in this case also known as decoupling agents, such as 2, 4-dinitrophenol), and their antibiotic activity has long been appreciated. It is also hypothesized their role as antiviral drugs and anticancer chemotherapeutic agents. Thinking of the structure of two of the most important ionophores, monensin A and valinomycin, respectively a polyether and a depsipeptide antibiotic, it is clear that they internally present many oxygen atoms (with related free electron doublets), indispensable for binding cations and transporting them through phospholipidic bilayers.

In Africa, this drug is given -- liberally -- to treat river blindness. 

From a reader:

So, here's why the case numbers are so low in that belt of Africa.  Guess what is widely distributed to treat river blindness.  And this chart is from the World Health Organization.

Numbers are from Johns Hopkins.


The audacity of "regulators" to force vaccination using EUA vaccines with less than one year's experience, while refusing to allow physicians to prescribe one of the safest drugs ever. And cheapest. To actually treat a deadly virus. 

How about a controlled study? Allow use of ivermectin in Florida but not in California.

Tribes Ask For Extension -- DAPL Update -- August 31, 2021

Re-posting:

Tribes ask for six-month extension: the US Army Corps of Engineers has decided to extend its timeframe for completing a court-ordered environmental study on the DAPL, according to information posted on the federal agency's Dakota Access project page. Link here.  Link to Williston Herald. 

According to court records, the Corps had been asked by tribes to extend the schedule by six months, and the federal agency said then it was considering granting the request. The decision will put publication of the Dakota Access pipeline’s final EIS somewhere around September of next year.

The outcome of the study will be a deciding factor in whether the U.S. Army Corps of Engineers reissues the easement for the Lake Oahe crossing, which was revoked last year.

Judge James Boasberg ruled that due to its controversial nature, NEPA required the Corps to complete the longer Environmental Impact Statement instead of the shorter Environmental Assessment when evaluating the pipeline’s easement to cross 90 feet below Lake Oahe.

Flashback: NASDAQ 100 / S&P 500 -- Update -- August 31, 2021

ZeroHedge a year ago. NASDAQ 100 / S&P 500 = 3.30

Nope, we did not peak? But pretty close. Today:

15,233 / 4,521 = 3.37

On another note, the S&P 500 has 328 all-time highs since the start of 2013. This is one more than the epic run from 1989 - 2000 in which the S&P 500 hit 327 all-time highs. Link here. Tea leaves suggest the current run is not yet over.

For 2021, to date: 53 record highs recorded. Link here.

**************************************

Europe, energy: unstoppable, natural gas, electricity and CO2 prices in Europe are setting new highs today, August 30, 2021. Triple-digit electricity prices are becoming common across Europe. Spanish day-ahead electricity prices are soaring. See next item.

Europe, energy: another day, another price increase for European power and natural gas. UK natural gas surges to an all-time high, traing above the equivalent of $17 per mBtu.

Meanwhile in Spain, the poster child for renewable energy, day-ahead electricity prices surge above $156 per MWh. And this is before winter arrives. Link here. 

Got coal? Rising energy prices send German inflation to 13-year high. Link to Tsvetana Paraskova.